RT @MOCBrasil: O papel do Mammaprint no tratamento adjuvante do Câncer de mama - Diretriz ASCO 2017 https://t.co/gDu53gRQOs @JCO_ASCO https…
O papel do Mammaprint no tratamento adjuvante do Câncer de mama - Diretriz ASCO 2017 https://t.co/gDu53gRQOs @JCO_ASCO https://t.co/XPS7NEdVlO
#biomarqueurs et décision de traitement systémique des #cancersdusein précoces, mise à jour des reco #ASCO https://t.co/O8C6Z4qLF3
Patients with lymph node positive breast cancer are recommended to get adjuvant chemotherapy based on the most... https://t.co/hZubQgp6Oi
NO more decisional role of Ki-67 for #adjuvant therapy in #EBC #breastcancer per @JCO_ASCO @ASCO recommendation https://t.co/rtdsVhgUZx
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @mtmurillo1: Practice guidelines biomarkers in breast cancer #bcsm @JCO_ASCO #radonc #cancerDeMama https://t.co/izIZhYiDvM
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
Practice guidelines biomarkers in breast cancer #bcsm @JCO_ASCO #radonc #cancerDeMama https://t.co/izIZhYiDvM
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @awolff: I am told that this is the “best ever” @ASCO guideline written ... 😎 #modesty @HopkinsKimmel https://t.co/5CcQmVT4GV
I am told that this is the “best ever” @ASCO guideline written ... 😎 #modesty @HopkinsKimmel https://t.co/5CcQmVT4GV
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
RT @JCO_ASCO: .@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ…
.@ASCO Practice Guideline: biomarkers guide decisions on adjuvant systemic therapy for early stage breast ca https://t.co/jxJ0mW7LLE #bcsm
Biomarcadors pr guiar decisions sobre teràpia adjuvant sistèmica dones amb 1a etapa càncer invasiu mama https://t.co/mLBCxFwHRb @ginebalear https://t.co/YPnH5SWAou
RT @OncoHebdo: #Test MammaPrint, actualisation du guide ASCO de pratique clinique sur l'utilisation des biomarqueurs publiée (JCO) https://…
#Test MammaPrint, actualisation du guide ASCO de pratique clinique sur l'utilisation des biomarqueurs publiée (JCO) https://t.co/O8C6Z4qLF3
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive #BreastCancer ASCO Update https://t.co/STLv6Gnfh1
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer https://t.co/Jcl1I5A6sw
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: https://t.co/tFp2lzDZ7Z
#MammaPrint may be used in patients with 1-3 positive nodes and high clinical risk to inform decisions on withholding adjuvant chemo #breast https://t.co/FL4X0qucOl
@ASCO ´s guidelines for Mammaprint use in #breastcancer : identify good progn pop• btw high risk https://t.co/aJ9hWy4vf9
.@ASCO recommendation on Mammaprint. very rigorous analysis by the team. Each word is deeply thought and matters ! https://t.co/bKWNEAlGhb